Data from CIMA-Q​

The CIMA-Q Data and Biological Samples Bank is a structured set of socio-demographic information, results of neuropsychological, neuropsychiatric and clinical assessments (including results of complete blood work) and biological samples from either healthy adults, adults with a cognitive complaint or living with Alzheimer’s. These data have been collected for more than 9 years from the CIMA-Q cohort and are available to researchers interested in Alzheimer’s disease and other related diseases.

Quick downloads

Detailed CIMA-Q Project Protocol (2022-12-15)

Data dictionary (french)

Demographics and initial diagnostic (french)

How can I access the CIMA-Q data

01.First you have to be a Consortium for the Early Identification of Alzheimer’s Disease – Quebec member.
Form to apply for a membership.
02.To access the CIMA-Q Bank, please ensure that you have your ethics approval letter for the research project. If your project has not been approved to date you must submit it to the Ageing and Neuroimaging Research Ethics Board (VN REB) for approval (https://criugm.qc.ca/la-recherche/comite-dethique-de-la-recherche/).
The ethics approval number must be provided to the databank manager in order to access the LORIS platform.
03.Appendix K: Complete the form describing the research project for which you intend to request access. Attach all relevant supporting documents to your application (see list at the end of Appendix K). The User Agreement(s) must be completed and signed by the principal investigator and the administrative representative of the investigator’s institution. Appendices B1 and B3 must be provided for all access applications whereas Appendix B2 must be provided only for biological material access applications.
04.Submit your documents to the User Access Committee (UAC) at: cimaq@criugm.qc.ca or directly to the Interim UAC Manager, Ms. France-Hélène Joncas
05.

Evaluation of your application by the UAC (evaluation within one week of receiving the complete file). One of the three following statuses might be issued by the UAC following your application:

  • Access denied
  • Access granted: When an application is accepted by the UAC, it will be submitted directly to the CIMA-Q Executive Committee for final approval.
  • Access granted /conditional (additional documents or information to be submitted).

If your application is accepted with conditions, you will have to respond to the UAC’s requests. Please submit to the following address: France-Helene.Joncas@crchudequebec.ulaval.ca

06.Issuance of the final approval letter for access to the CIMA-Q Data and Biomaterial Bank by the Executive Committee once the user agreements have been signed by the CIUSSS CS MTL administrative manager who oversees the CIMA-Q project.
07.Access:
To Access: CLINICAL / SOCIO-DEMOGRAPHIC / BIOLOGICAL / NEUROPSYCHOLOGICAL / IMAGING DATA
Contact the LORIS platform manager who will grant you access codes to access the data:
pierre-emmanuel.morin.ccsmtl@ssss.gouv.qc.ca

To access: BIOMATERIAL
Contact: Frederic.Calon@pha.ulaval.ca President of the CIMA-Q BioBank
France-Helene.Joncas@crchudequebec.ulaval.ca Interim Coordinator of the CIMA-Q BioBank

Please note: biological material is reserved for Quebec members only. If you are outside of Quebec, please inquire about the possibility of collaborating with a Quebec researcher.

As of July 2023:
PARTICIPANTS: 412 +
H :35.7 % F: 64.3 %

Controls (C): 16.5 %
Subjective cognitive decline (SCD): 43.2 %
Mild cognitive impairment (MCI): 31.6 %
Alzheimer’s Disease (AD): 8.7 %

FULL ASSESSMENT
(Clinical + Neuropsychology + Blood sample)
Initial evaluation: 412 (+241 MRI)
post 2 years follow-up:  184 (+112 MRI)
post 4 years follow-up: 134 (+53 MRI)
post 6 years follow-up:  109 (+58 MRI)
post 8 years follow-up:  23 (+11 MRI)

Full assessment total (Clinical + Neuropsychology + blood collection): 862
Participants with at least 1 complete follow-up after initial evaluation: 222
Participants with 1 follow-up evaluation: 86
Participants with 2 follow-up evaluations: 62
Participants with 3 follow-up evaluations: 54
Participants with 4 follow-up evaluations: 20

NEUROIMAGING
Total PET-scans: 29
Total MRI: 475
Participants with at least 1 MRI: 278
Participants with 1 MRI: 153
Participants with 2 MRI: 78
Participants with 3 MRI: 27
Participants with 4 MRI: 15
Participants with 5 MRI: 5

BIOSAMPLES
Blood 19 000+
CSF (60 participants) 6000+
CSF young controls: to come

BRAIN BANK: 4

All Data and Biomaterial available in the CIMA-Q bank

CLINICAL ASSESSMENT

NURSE AND MEDICAL DOCTOR ASSESSMENT

  1. Telephone-Mini Mental State Examination
  2. Socio-demographic information
  3. Logical Memory test from the Wechsler Memory Scale (short story, immediate and delayed recall)
  4. Cognitive reserve questionnaire (Bartrés score)
  5. Self-perception of health and smoking
  6. Health status – measurements (vital signs)
  7.  Walking speed
  8. Grip strength
  9. Mini Nutritional Assessment® SF
  10. Allergies
  11. List of current medications
  12. Questions relating to sleep disorders
  13. Alzheimer’s disease cooperative study (ADCS) – Activities of
    Daily Living questionnaire
  14. PHQ-9 (Patient Health Questionnaire)
  15. MoCA (Montreal Cognitive Assessment)
  16. Medical history
  17. Physical examination
  18. Neurological examination
  19. Neuropsychiatric Inventory (NPI-Q)
  20. Score – Clinical Dementia Rating (CDR)
  21. Hachinski Ischemic Scale
  22. Clinical diagnosis
  23. Clinical inclusion/exclusion criteria
  24. Mild Behavioral Impairment Checklist (MBI-C)
  25. Gender identity
  26. Smell identification test (UPSIT)
  27. Biochemistry profile
  28. Hematology profile
  29. Anxiety vs COVID-19

HOME QUESTIONNAIRES

  1. Geriatric Depression Scale (GDS-30)
  2. Cognitive Change Index (CCI)
  3. Memory Self-Evaluation (QAM, short form)
  4. Geriatric Anxiety Inventory (GAI)
  5. Epworth Sleepiness Scale (Epworth)
  6. Insomnia Severity Index (ISI)
  7. Questions on bilingualism
  8. Chronic pain Self-Assessment
  9. Technology experience profile
  10. Mobile Device Proficiency
  11. Short Form health and well-being survey (SF-36)
  12. Perception Regarding Investigational Screening for Memory in Primary Care
  13. Dementia Attitude Scale (DAS)
  14. Knowledge about Alzheimer’s disease
  15. Siegrist’s Questionnaire (effort-reward imbalance)
  16. Karasek’s Questionnaire (Work and professional relationships)

STUDY PARTNER QUESTIONNAIRES

  1. Cognitive complaint question (Jessen)
  2. Neuropsychiatric Inventory (NPI-Q),
  3. Apathy Inventory (AI)
  4. Questionnaire relating to activities of daily living (ADCS-PI)
  5. Mild Behavioral Impairment Checklist (MBI-C)

NEUROPSYCHOLOGICAL ASSESSMENT

MEMORY

  1. 15 Word list / episodic memory (Rey Auditory Verbal Learning Task, RAVLT)
  2. Envelope Task (prospective memory)
  3. Face-Name memory test (associative episodic memory)
  4. Cued recall from Memoria (episodic memory)

PERCEPTION

  1. Object Decision test / Birmingham Object Recognition Battery (BORB)
  2. Visual Perception line orientation test (BORB)

EXECUTIVE FUNCTIONS

  1. Stroop-D-KEFS (4 conditions)
  2. Trail making test A and B
  3. Computerized Hayling task
  4. Digit Symbol test from the WAIS-III
  5. Alpha-span (short version)

LANGUAGE

  1. Verbal fluency (category – animals)
  2. Boston Naming Test
  3. Vocabulary test (WAIS-III)

PSYCHIATRIC SX and SLEEP

  1. Apathy Inventory questionnaire
  2. Questions on sleep habits

MRI ASSESSMENT

ANATOMICAL 3DT1w
PATHOLOGICAL PD and T2w
VASCULAR Flair and T2*

CONNECTIVITY / FUNCTIONAL

  1. 30-direction DTI
  2. Resting state BOLD
  3. Task related activation
And PET SCANS 

BLOOD BIOSAMPLES

  1. Plasma
  2. Serum
  3. Red blood cells
  4. PBMCs / iPSC / iPSC-derived neurons
  5. DNA / Buffy coat
  6. RNA

RESULTS:

  1. p-Tau 181 / p-Tau 231
  2. Apo E genotype

CSF BIOSAMPLES (60 participants)

RESULTS:

  1. Aβ40 / Aβ42 / Aβ38
  2. Total Tau 

BRAIN BANK

Data collected during the COVID-19 pandemic lockdown

Through a collaboration, the cognitively healthy CIMA-Q participants were interviewed during the first lockdown regarding parameters suspected to be modified by the sanitary measures and the COVID-19 pandemic. The following set of questionnaires assessed COVID-19-related stress, psychiatric symptoms, subjective cognitive complaints, changes in social, cognitive, and physical stimulation, as well as adherence to social distancing recommendations.

  1. Socio-demographic information
  2. T-MMSE
  3. COVID-19 restrictions
  4. COVID-19 virus
  5. Social distancing recommandations
  6. Social network
  7. Changes in sleep routine
  8. Sleep habits
  9. Insomnia Severity Index (ISI)
  1. Physical activity
  2. Geriatric Anxiety Inventory (GAI)
  3. Problems and symptoms related to the pandemic
  4. Self-perception of health
  5. Geriatric Depression Scale (GDS-30)
  6. Question on memory (Jessen)
  7. Short QAM
  8. Pain Self-Assessment Questionnaire (short form)
  9. Alcohol and drug use